Remimazolam

Generic Name: Remimazolam

Brand Names: Byfavo

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉BrN_₄O_₂

CAS Number: 308242-62-8

Unique Ingredient Identifier: 7V4A8U16MB

Background: Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid biotran...

Indication: Remimazolam is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.

Associated Conditions: Procedural Sedation

Associated Therapies: -

Clinical Trials

The Comparison of Hypotension Incidence Between Remimazolam and Propofol in Hypertensive Patients Undergoing Neurosurgery

Not Applicable

Completed

Conditions: Patients Undergoing Neurosurgery

Interventions: Drug: propofol
Drug: remimazolam

First Posted Date: 2021-12-20

Last Posted Date: 2022-11-07

Lead Sponsor: Yonsei University

Target Recruit Count: 100

Registration Number: NCT05164146

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Effect of Remimazolam With Protocolized Sedation on Critical Ill, Mechanical Ventilated Patients Compared With Midazolam

Not Applicable

Recruiting

Conditions: Sedation and Analgesia

Interventions: Drug: Remimazolam
Drug: Midazolam

First Posted Date: 2021-12-16

Last Posted Date: 2023-07-14

Lead Sponsor: Zhujiang Hospital

Target Recruit Count: 440

Registration Number: NCT05160987

Locations: 🇨🇳
Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University, Guangzhou, Guangdong, China

The 90% Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg

Not Applicable

Conditions: Anesthesia

Interventions: Drug: Remimazolam

First Posted Date: 2021-09-22

Last Posted Date: 2021-12-20

Lead Sponsor: Jianbo Yu

Target Recruit Count: 120

Registration Number: NCT05053763

Locations: 🇨🇳
Tianjin Nankai Hospital, Tianjin, Tianjin, China

Remimazolam and Remifentanil Without Neuromuscular Blocking Agent

Completed

Conditions: Myoma;Uterus
Unspecified Condition Associated With Female Genital Organs and Menstrual Cycle
Polyp Endometrium

Interventions: Drug: Remimazolam

First Posted Date: 2021-08-27

Last Posted Date: 2022-04-25

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 38

Registration Number: NCT05025410

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

Comparison of Postoperative QoR-15 Scores Between Desflurane and Remimazolam in Lumbar Fusion Surgery

Not Applicable

Completed

Conditions: Lumbar Fusion Surgery

Interventions: Drug: Desﬂurane
Drug: Remimazolam

First Posted Date: 2021-07-30

Last Posted Date: 2024-04-30

Lead Sponsor: Gangnam Severance Hospital

Target Recruit Count: 76

Registration Number: NCT04983966

Locations: 🇰🇷
GangnamSeverance Hospital, Seoul, Korea, Republic of

The Median Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg

Phase 4

Conditions: Anesthesia

Interventions: Drug: Remimazolam

First Posted Date: 2021-07-20

Last Posted Date: 2022-01-10

Lead Sponsor: Tianjin Nankai Hospital

Target Recruit Count: 50

Registration Number: NCT04969068

Locations: 🇨🇳
Tianjin Nankai Hospital, Tianjin, Tianjin, China

Remimazolam and Endovascular Procedures of Cerebrovascular Diseases

Not Applicable

Completed

Conditions: Cerebrovascular Disorders
Anesthesia

Interventions: Drug: remimazolam
Drug: propofol

First Posted Date: 2021-07-06

Last Posted Date: 2022-10-20

Lead Sponsor: Air Force Military Medical University, China

Target Recruit Count: 142

Registration Number: NCT04950621

Locations: 🇨🇳
Xijing hospital, Xi'an, Shaanxi, China

A Randomized Single-blind Clinical Trial of the Efficacy and Safety of Remimazolam in Painless Bronchoscopy

Phase 4

Conditions: Bronchoscopy
Sedation

Interventions: Drug: Remimazolam
Drug: Dexmedetomidine

First Posted Date: 2021-06-09

Last Posted Date: 2021-06-09

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 364

Registration Number: NCT04919174

Locations: 🇨🇳
The Second Affiliated Hospital of Zhejiang University Medical College, Hangzhou, Zhejiang, China

Remimazolam and Postoperative Nausea and Vomiting in High-risk Patients

Phase 4

Completed

Conditions: Postoperative Nausea and Vomiting
High-risk Patients
Benzodiazepine

Interventions: Drug: Placebo
Drug: Remimazolam

First Posted Date: 2021-04-27

Last Posted Date: 2024-01-03

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 552

Registration Number: NCT04861337

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳
Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China

and more 7 locations

Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures

Phase 2

Active, not recruiting

Conditions: Pediatric ALL

Interventions: Drug: Remimazolam

First Posted Date: 2021-04-20

Last Posted Date: 2022-12-14

Lead Sponsor: Acacia Pharma Ltd

Target Recruit Count: 100

Registration Number: NCT04851717

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇩🇰
Odense Universitetshospital, Odense, Denmark
🇺🇸
Stanford University, Palo Alto, California, United States

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy